Migraine trials recruiting in Nebraska

All Migraine trials nationally

Cities in Nebraska

Recruiting trials in Nebraska

• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
  NCT07018713 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Nebraska: Omaha
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
  NCT07018700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Nebraska: Omaha
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
  NCT06810505 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Nebraska: Papillion
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  NCT05711394 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Nebraska: Papillion
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Nebraska: Papillion
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
  NCT06641466 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · Nebraska: Papillion
• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
  NCT06995729 · Phase: Phase 1 · Ages: 6 Years to 11 Years · Sex: All (male and female) · Nebraska: Omaha
• Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
  NCT06972056 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Nebraska: Omaha
• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
  NCT05156398 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Nebraska: Grand Island, Papillion
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
  NCT04743141 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Nebraska: Lincoln, Omaha
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Nebraska: Lincoln, Omaha
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Nebraska: Papillion
• Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
  NCT07310290 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Nebraska: Grand Island